Compare Stocks

→ “Forget Tesla, this is Elon’s Next Big Thing” (From InvestorPlace) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CHFS Nuwellis	$0.37	$4.79	$4.86 ▼ $37.50	$2.22M	1.55	467,323 shs	54,015 shs
ECOR electroCore	$5.67 -1.2%	$6.57	$3.83 ▼ $8.08	$34.46M	0.91	13,398 shs	5,248 shs
SLNO Soleno Therapeutics	$38.52 +3.7%	$44.72	$3.00 ▼ $53.82	$1.25B	-1.56	301,646 shs	290,931 shs
VANI Vivani Medical	$2.02 -2.4%	$1.80	$0.84 ▼ $7.80	$111.06M	3.27	2.71 million shs	183,606 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CHFS Nuwellis	+0.85%	-4.24%	-10.06%	-15.22%	-90.86%
ECOR electroCore	-1.22%	-3.08%	-14.61%	-12.50%	-10.14%
SLNO Soleno Therapeutics	+3.72%	-4.44%	-11.37%	-14.32%	+1,092.57%
VANI Vivani Medical	-2.42%	-7.34%	+2.54%	+100.00%	+100.00%

A.I. “Perfect Storm” Could Send THESE Stocks Sky High (Ad)

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

>>Check out what this A.I. Perfect Storm is<<

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CHFS Nuwellis	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ECOR electroCore	2.9617 of 5 stars	3.5	5.0	0.0	0.0	3.3	0.8	0.6
SLNO Soleno Therapeutics	4.3357 of 5 stars	3.5	1.0	0.0	4.6	3.2	4.2	0.6
VANI Vivani Medical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CHFS Nuwellis	N/A	N/A	N/A	N/A
ECOR electroCore	3.00	Buy	$10.00	76.37% Upside
SLNO Soleno Therapeutics	3.00	Buy	$55.60	44.34% Upside
VANI Vivani Medical	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest CHFS, SLNO, ECOR, and VANI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/14/2024	ECOR electroCore	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
2/5/2024	SLNO Soleno Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$93.00
1/23/2024	SLNO Soleno Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$63.00

(Data available from 4/16/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CHFS Nuwellis	$5.51M	0.40	N/A	N/A	$12.79 per share	0.03
ECOR electroCore	$16.03M	2.12	N/A	N/A	$1.24 per share	4.57
SLNO Soleno Therapeutics	N/A	N/A	N/A	N/A	$5.16 per share	N/A
VANI Vivani Medical	N/A	N/A	N/A	N/A	$0.41 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CHFS Nuwellis	-$18.11M	-$279.28	N/A	N/A	N/A	-254.26%	-173.61%	-131.01%	N/A
ECOR electroCore	-$18.83M	-$3.56	N/A	N/A	N/A	-117.49%	-201.47%	-109.61%	5/1/2024 (Estimated)
SLNO Soleno Therapeutics	-$38.99M	-$2.97	N/A	N/A	N/A	N/A	-79.65%	-52.92%	5/14/2024 (Estimated)
VANI Vivani Medical	-$25.65M	-$0.50	N/A	∞	N/A	N/A	-87.15%	-50.47%	5/20/2024 (Estimated)

Latest CHFS, SLNO, ECOR, and VANI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/13/2024	Q4 2023	ECOR electroCore	-$0.55	-$0.61	-$0.06	-$0.61	$5.23 million	$5.19 million
3/6/2024	Q4 2023	SLNO Soleno Therapeutics	-$0.31	-$0.33	-$0.02	-$0.33	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CHFS Nuwellis	N/A	N/A	N/A	N/A	N/A
ECOR electroCore	N/A	N/A	N/A	N/A	N/A
SLNO Soleno Therapeutics	N/A	N/A	N/A	N/A	N/A
VANI Vivani Medical	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CHFS Nuwellis	N/A	6.87	5.97
ECOR electroCore	N/A	1.76	1.49
SLNO Soleno Therapeutics	N/A	14.89	14.89
VANI Vivani Medical	N/A	4.03	4.03

Ownership

Institutional Ownership

Company	Institutional Ownership
CHFS Nuwellis	65.06%
ECOR electroCore	26.74%
SLNO Soleno Therapeutics	97.42%
VANI Vivani Medical	6.78%

Insider Ownership

Company	Insider Ownership
CHFS Nuwellis	0.60%
ECOR electroCore	13.14%
SLNO Soleno Therapeutics	28.80%
VANI Vivani Medical	55.62%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CHFS Nuwellis	66	6.04 million	N/A	Not Optionable
ECOR electroCore	68	6.00 million	5.21 million	Not Optionable
SLNO Soleno Therapeutics	33	32.46 million	23.11 million	Optionable
VANI Vivani Medical	44	54.98 million	24.40 million	Optionable

CHFS, SLNO, ECOR, and VANI Headlines

Source	Headline
	Short Interest in Vivani Medical, Inc. (NASDAQ:VANI) Expands By 420.1% marketbeat.com - March 27 at 4:22 PM
	Vivani Medical: Q4 Earnings Snapshot sfgate.com - March 26 at 9:53 PM
	Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results finance.yahoo.com - March 26 at 9:52 PM
	Vivani Medical Inc (VANI) Reports Fourth Quarter and Full Year 2023 Financial Results finance.yahoo.com - March 26 at 9:52 PM
	VANI Stock Earnings: Vivani Medical Beats EPS for Q4 2023 investorplace.com - March 26 at 3:01 PM
	VANI May 2024 6.000 call finance.yahoo.com - March 16 at 8:08 AM
	VANI Aug 2024 6.000 call finance.yahoo.com - March 16 at 8:08 AM
	VANI Apr 2024 1.000 call finance.yahoo.com - March 16 at 3:07 AM
	Thinking about buying stock in Ocean Biomedical, Rush Street Interactive, Vivani Medical, Abeona Therapeutics, or Honest Company? morningstar.com - March 9 at 12:41 PM
	Vivani Medical Appoints Daniel Bradbury to its Board of Directors finance.yahoo.com - March 6 at 4:14 PM
	Vivani Medical Surges on its Ozempic-Like Weight-Loss Implant marketbeat.com - March 6 at 6:14 AM
	Vivani Medical Surges on its Ozempic-Like Weight-Loss Implant marketbeat.com - March 6 at 6:13 AM
	Vivani Medical, Altamira Therapeutics, Quoin Pharmaceuticals among healthcare movers msn.com - March 4 at 10:16 AM
	VANI Mar 2024 2.500 put finance.yahoo.com - March 3 at 11:20 PM
	Vivani Medical announces pricing of $15M registered direct offering msn.com - March 1 at 1:22 PM
	Vivani Medical Shares Retreat 20% on Securities Purchase Agreement marketwatch.com - March 1 at 1:22 PM
	Vivani Medical Prices $15 Mln Direct Offering; Stock Down Over 20% In Pre-market markets.businessinsider.com - March 1 at 1:22 PM
	Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants businesswire.com - March 1 at 7:49 AM
	Individual investors invested in Vivani Medical, Inc. (NASDAQ:VANI) up 287% last week, insiders too were rewarded finance.yahoo.com - March 1 at 7:42 AM
	Doctors, advocates hail federal diabetes drug plan as potentially 'life-changing' ca.news.yahoo.com - February 29 at 4:42 PM
	Vivani Medical (VANI) stock price surged: is it a good buy? invezz.com - February 29 at 11:42 AM
	It's not 'all in their head.' Heart disease is misdiagnosed in women. And it's killing us. ca.news.yahoo.com - February 29 at 6:41 AM
	Vivani has positive data for long-term drug-eluting weight loss implant as it shifts strategy drugdeliverybusiness.com - February 28 at 5:58 PM
	Vivani Medical surges after animal data on obesity implants msn.com - February 28 at 5:58 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
4 Stocks to Buy Before the Fed Cuts Interest Rates
March 19, 2024 7:49 AM
View 4 Stocks to Buy Before the Fed Cuts Interest Rates
Chipotle Stock Shoots Higher, Announcing 50 for 1 Stock Split
March 20, 2024 10:26 AM
View Chipotle Stock Shoots Higher, Announcing 50 for 1 Stock Split
Delta Air Lines Stock Should Take Flight After Solid Report
April 10, 2024 8:41 AM
View Delta Air Lines Stock Should Take Flight After Solid Report
TKO Group Knocks Out WrestleMania Event Record
April 15, 2024 7:20 AM
View TKO Group Knocks Out WrestleMania Event Record

All Headlines

Company Descriptions

Nuwellis

NASDAQ:CHFS

Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.

electroCore

NASDAQ:ECOR

electroCore, Inc., a commercial-stage bioelectronic medicine and wellness company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults; Truvaga for the support of general health and wellbeing; and TAC-STIM, a form of nVNS for human performance. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

Soleno Therapeutics

NASDAQ:SLNO

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Vivani Medical

NASDAQ:VANI

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial